Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors
Open Access
- 1 January 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 2 (1) , vdaa051
Abstract
Atypical Teratoid/Rhabdoid tumor (AT/RT) remains a difficult-to-treat tumor with a five-year overall survival rate of 15-45%. Proteasome inhibition has recently been opened as an avenue for cancer treatment with the FDA approval of bortezomib (BTZ) in 2003 and carfilzomib (CFZ) in 2012. The aim of this study was to identify and characterize a pre-approved targeted therapy with potential for clinical trials in AT/RT. We performed a drug screen using a panel of 134 FDA-approved drugs in three AT/RT cell lines. Follow-on in vitro studies used six cell lines and patient-derived short-term cultures to characterize selected drug interactions with AT/RT. In vivo efficacy was evaluated using patient derived xenografts in an intracranial murine model. BTZ and CFZ are highly effective in vitro, producing some of the strongest growth-inhibition responses of the evaluated 134-drug panel. Marizomib (MRZ), a proteasome inhibitor known to pass the blood brain barrier (BBB), also strongly inhibits AT/RT proteasomes and generates rapid cell death at clinically-achievable doses in established cell lines and freshly patient-derived tumor lines. MRZ also significantly extends survival in an intracranial mouse model of AT/RT. Marizomib (MRZ) is a newer proteasome inhibitor which has been shown to cross the BBB and is already in phase II clinical trials for adult high-grade glioma (NCT NCT02330562 and NCT02903069). MRZ strongly inhibits AT/RT cell growth both in vitro and in vivo via a moderately well-characterized mechanism, and has direct translational potential for patients with AT/RT.Keywords
Funding Information
- TeamConnor Childhood Cancer Foundation
- Morgan Adams Foundation
- National Institutes of Health
- National Cancer Institute (K08CA193982)
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS107313)
- Boettcher Foundation Webb-Waring Biomedical Research
- University of Colorado (P30CA046934)
This publication has 36 references indexed in Scilit:
- Modulation of pediatric brain tumor autophagy and chemosensitivityJournal of Neuro-Oncology, 2011
- SWI/SNF nucleosome remodellers and cancerNature Reviews Cancer, 2011
- Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8Cell Death & Differentiation, 2011
- Frequent hSNF5/INI1 Germline Mutations in Patients with Rhabdoid TumorClinical Cancer Research, 2011
- Childhood Atypical Teratoid Rhabdoid Tumor of the Central Nervous SystemJournal of Pediatric Hematology/Oncology, 2009
- Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing programPediatric Blood & Cancer, 2007
- Impact of radiotherapy for pediatric CNS atypical teratoid/rhabdoid tumor (single institute experience)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from BortezomibCancer Cell, 2005
- Atypical Teratoid/Rhabdoid Tumors (ATRT): Improved Survival in Children 3 Years of Age and Older With Radiation Therapy and High-Dose Alkylator-Based ChemotherapyJournal of Clinical Oncology, 2005
- Phase I Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study (ADVL0015)Journal of Clinical Oncology, 2004